Plague vaccine 2 is under clinical development by Lanzhou Institute of Biological Products and currently in Phase II for Plague. According to GlobalData, Phase II drugs for Plague have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Plague vaccine 2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Plague vaccine 2 overview

Vaccine candidate is under development for the prevention of plague. It is a subunit vaccine comprised of natural F1 antigen and recombined V antigen. It is administered through intramuscular route.

Lanzhou Institute of Biological Products overview

Lanzhou Institute of Biological Products is engaged in the manufacture of medical and orthopaedic goods and hospital equipment and supplies which is a producer of instruments, apparatus, and equipment to medical and dental practitioners, clinics, and hospitals The company is Headquartered in China.

For a complete picture of Plague vaccine 2’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.